GHRP-6 — growth hormone-releasing peptide, first generation
In short
Synthetic hexapeptide and ghrelin receptor agonist studied for stimulating somatotropic secretion and appetite.
Overview
-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release through activation of the ghrelin receptor (GHS-R1a) and CD36 receptor. Developed in the 1980s as one of the first growth hormone secretagogues, it acts through a PKC/calcium-dependent pathway distinct from
Activates GHS-R1a (ghrelin receptor) for release through a PKC/calcium-dependent, cAMP-independent pathway via diacylglycerol/inositol trisphosphate signaling at both pituitary and hypothalamic sites. Separately acts as a CD36 receptor antagonist, blocking fatty acid uptake and providing cytoprotective and cardioprotective effects by preventing lipotoxicity. Requires endogenous for maximal stimulation— antagonist reduces -6-induced response by ~80% (Pandya et al., 1998). Exhibits tachyphylaxis with continuous exposure, necessitating pulsed dosing strategies.
Molecular information
First-order decay curve at 0.5h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Unique ability to raise feeding motivation without activating peripheral metabolic hormones - clean centrally-driven appetite signal.
Доказана безопасност в клинично изпитване фаза I при хора с интравенозно приложение. Очаква се силно повишаване на апетита поради активиране на грелиновия рецептор. Повишава преходно нивата на кортизол и пролактин, особено при дози над 100 мкг. Може да повиши кръвната захар и да намали инсулиновата чувствителност при продължителна употреба. Наблюдавайте показателите при диабет или инсулинова резистентност. Избягвайте приложение при активен рак, тъй като повишаването на / може да стимулира туморния растеж. Инжектирайте на празен стомах, тъй като храната притъпява отговора на растежния хормон. -6 е по-малко селективен от ипаморелин. Не показва фармакологично взаимодействие с бета-блокера метопролол в клинични проучвания. Продължителната непрекъсната употреба може да доведе до десенсибилизация на грелиновия рецептор (GHS-R1a). Препоръчва се цикличност (8-12 седмици употреба, 4-8 седмици почивка) за поддържане на ефикасността. Сигнали за спиране: Персистираща задръжка на вода или оток. Признаци на синдром на карпалния тунел (изтръпване на ръцете). Значително повишаване на кръвната захар. Гинекомастия или чувствителност на зърната. Болка в ставите извън първоначалната адаптация. Всякакви признаци на алергична реакция. Консултирайте се с медицински специалист при тревожни симптоми.
4 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Pong - GH release kinetics
Clinical | 1 mcg/kg | single | GH +10-15x baseline in 30-60 min
Mol Endocrinol · 1996
View the studyInformation about GHRP-6 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
